A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Start Date
4/17/2026
Completion Date
2/1/2030
Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
LY4584180
Rituximab
Conditions
Locations
Mayo Clinic - Scottsdale
Scottsdale, Arizona 85259
United States
City of Hope
Duarte, California 91010
United States
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California 90059
United States
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco, California 94158
United States
Colorado Blood Cancer Institute
Denver, Colorado 80218
United States
University of Miami - Sylvester Cancer Center
Miami, Florida 33136
United States
Florida Cancer Specialists - Sarasota
Sarasota, Florida 34236
United States
Emory University Hospital
Atlanta, Georgia 30322
United States
Massachusetts General Hospital
Boston, Massachusetts 02114
United States
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States
Mayo Clinic - Rochester
Rochester, Minnesota 55905
United States
Columbia University
New York, New York 10032
United States
University of Rochester
Rochester, New York 14618
United States
The Ohio State University (OSU)
Columbus, Ohio 43210
United States
Oregon Health & Science University (OHSU)
Portland, Oregon 97239
United States
Sarah Cannon Research Institute
Nashville, Tennessee 37203
United States
Vanderbilt University Medical Center
Nashville, Tennessee 37212
United States
Texas Oncology - DFW (Sammons CC)
Dallas, Texas 75246
United States
Baylor College of Medicine
Houston, Texas 77030
United States
University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)
Seattle, Washington 98195
United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin 53226
United States
CHU de Nantes - Hotel-Dieu
Nantes, 44093
France
Institut Curie
Paris, 75005
France
CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie
Pessac, 33604
France
HCL Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495
France
Oncopole Claudius Regaud
Toulouse, 31059
France
Charite Universitaetsmedizin Berlin
Berlin, 10117
Germany
Universitaetsklinikum Koeln (AoeR)
Cologne, 50937
Germany
Universitaetsklinikum Essen
Essen, 45147
Germany
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet
Frankfurt am Main, 60590
Germany
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, 40138
Italy
Istituto Europeo di Oncologia
Milan, 20141
Italy
National Cancer Center Hospital East
Chiba, 277-8577
Japan
Okayama University Hospital
Okayama, 700-8558,
Japan
Cancer Institute Hospital of JFCR
Tokyo, 135-8550
Japan
Pratia Onkologia Katowice
Katowice, 40-519
Poland
Pratia MCM Krakow
Krakow, 30-727
Poland
AIDPORT Sp. z o.o.
Skorzewo, 60-185
Poland
Instytut Hematologii i Transfuzjologii w Warszawie
Warsaw, 02-776
Poland
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, 08908
Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, 28040
Spain
King's College Hospital
London, SE5 9RS
United Kingdom
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ
United Kingdom
Nottingham City Hospital
Nottingham, NG5 1PB
United Kingdom
Derriford Hospital
Plymouth, PL6 8DH
United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, SO16 6YD
United Kingdom